[go: up one dir, main page]

NO801469L - Pyrimidinforbindelser og fremgangsmaate til deres fremstilling - Google Patents

Pyrimidinforbindelser og fremgangsmaate til deres fremstilling

Info

Publication number
NO801469L
NO801469L NO801469A NO801469A NO801469L NO 801469 L NO801469 L NO 801469L NO 801469 A NO801469 A NO 801469A NO 801469 A NO801469 A NO 801469A NO 801469 L NO801469 L NO 801469L
Authority
NO
Norway
Prior art keywords
pyrimid
procedures
compounds
preparation
pyrimid compounds
Prior art date
Application number
NO801469A
Other languages
English (en)
Inventor
Adrian Marxer
Kurt Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO801469L publication Critical patent/NO801469L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO801469A 1979-05-18 1980-05-16 Pyrimidinforbindelser og fremgangsmaate til deres fremstilling NO801469L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
NO801469L true NO801469L (no) 1980-11-19

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
NO801469A NO801469L (no) 1979-05-18 1980-05-16 Pyrimidinforbindelser og fremgangsmaate til deres fremstilling

Country Status (21)

Country Link
EP (1) EP0019811A1 (no)
JP (1) JPS55154971A (no)
KR (1) KR830002757A (no)
AR (1) AR228256A1 (no)
AU (1) AU5848480A (no)
DD (1) DD150609A5 (no)
DK (1) DK214480A (no)
ES (1) ES491514A0 (no)
FI (1) FI801600A7 (no)
GB (1) GB2052487B (no)
GR (1) GR68453B (no)
IE (1) IE49803B1 (no)
IL (1) IL60086A (no)
MA (1) MA18829A1 (no)
NO (1) NO801469L (no)
NZ (1) NZ193730A (no)
OA (1) OA06533A (no)
PL (1) PL224313A1 (no)
PT (1) PT71251A (no)
ZA (1) ZA802909B (no)
ZW (1) ZW11880A1 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
EP0954316A4 (en) * 1997-09-03 2002-02-13 Lilly Co Eli PYRIMIDINE DERIVATIVES
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432222C (en) 2000-12-21 2008-07-29 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP2140862A3 (en) * 2001-01-31 2010-02-17 H.Lundbeck A/S Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods
SI1483247T1 (sl) 2002-03-13 2009-12-31 Euro Celtique Sa Arilno substituirani pirimidini in njihova uporaba
ATE366045T1 (de) * 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN101037438A (zh) 2002-08-02 2007-09-19 沃泰克斯药物股份有限公司 用作gsk-3的抑制剂的吡唑组合物
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
EP1917259B1 (en) 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
SG166827A1 (en) 2005-11-03 2010-12-29 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
MX2009004807A (es) 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
DE602007007985D1 (de) 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
CN101663295B (zh) 2007-03-09 2014-11-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶类化合物
MX2009009591A (es) 2007-03-09 2009-11-10 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009009592A (es) 2007-03-09 2009-11-10 Vertex Pharma Aminopiridinas utiles como inhibidores de proteinas cinasas.
CN101679386A (zh) 2007-04-13 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
WO2008137621A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP2152694A2 (en) 2007-05-02 2010-02-17 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CA2694499A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
JP2012501971A (ja) 2008-09-03 2012-01-26 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶および共結晶を含む薬学的処方物
UY32306A (es) * 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
EP4243826A1 (en) * 2020-11-12 2023-09-20 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
JPS55154971A (en) 1980-12-02
ES8104279A1 (es) 1981-04-16
IL60086A0 (en) 1980-07-31
IE801023L (en) 1980-11-18
MA18829A1 (fr) 1980-12-31
IE49803B1 (en) 1985-12-25
FI801600A7 (fi) 1981-01-01
GB2052487B (en) 1983-05-11
OA06533A (fr) 1981-07-31
EP0019811A1 (de) 1980-12-10
ZW11880A1 (en) 1980-12-17
PT71251A (en) 1980-06-01
DK214480A (da) 1980-11-19
PL224313A1 (no) 1981-02-13
AU5848480A (en) 1980-11-20
NZ193730A (en) 1982-12-21
ZA802909B (en) 1981-05-27
AR228256A1 (es) 1983-02-15
IL60086A (en) 1984-03-30
GB2052487A (en) 1981-01-28
GR68453B (no) 1981-12-30
DD150609A5 (de) 1981-09-09
KR830002757A (ko) 1983-05-30
ES491514A0 (es) 1981-04-16

Similar Documents

Publication Publication Date Title
NO801469L (no) Pyrimidinforbindelser og fremgangsmaate til deres fremstilling
NO813804L (no) Substituerte pyrimidiner og fremgangsmaate for deres fremstilling
DK211382A (da) Cephalosporinderivater og fremgangsmaade til deres fremstilling
DK338379A (da) Pyrazinderivater og fremgangsmaade til deres fremstilling
DK3880A (da) Fremgangsmaade til fremstilling af peptidylargininaldehydderivater og disses anvendelse
DK43981A (da) Kompositmaterialer og fremgangsmaade til deres fremstilling
DK149623C (da) Fremgangsmaade til fremstilling af alfa-hydroxycarboxylsyreamider
DK153791C (da) Fremgangsmaade til fremstilling af 7-hydroxycumaraner
DK345977A (da) G rifamycinforbindelser og fremgangsmaade til deres fremstillin
DK401882A (da) Cyclopentadienderivater og fremgangsmaader til deres fremstilling
DK159851C (da) Fremgangsmaade til fremstilling af riboflavin
DK251281A (da) N6-adenosiner og fremgangsmaader til deres fremstilling
NO780800L (no) Azoforbindelser og fremgangsmaate til deres fremstilling
DK409277A (da) Pentapeptider og fremgangsmaade til deres fremstilling
DK81380A (da) Fremgangsmaade til indramning
DK63080A (da) 25-hydroxy-24-oxochlostanderivater og fremgangsmaade til fremstilling deraf
IT8048889A0 (it) Composti perfluoroalchilici e procedimento per prepararli
DK111678A (da) Enzym-marumer og fremgangsmaade til deres fremstilling
DK243380A (da) Praeformede banelignende strukturer og fremgangsmaade til deres fremstilling
NO790047L (no) Kompoundmaterialer og fremgangsmaate til deres fremstilling
DK24280A (da) Spiro-quinolylhydantoiner fremgangsmaade til deres fremstilling og deres anvendelse
DK21579A (da) 5-phenethyl-2-oxazolidon-derivater og fremgangsmaade til deres fremstilling
DK416278A (da) 2-oxazolidon-derivater og fremgangsmaade til deres fremstilling
NO821206L (no) Imidazolderivater og fremgangsmaate for deres fremstilling
NO821108L (no) 5-fluor pgi-forbindelser og fremgangsmaate for deres fremstilling